Palliative care for patients with non-malignant end stage respiratory disease

K M Hill, M F Muers

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality in the United Kingdom; 28 000 people in England and Wales died of the disease in 1999, a figure comparable with lung cancer which killed 29 000 people in the same year.1 Equal numbers of patients with COPD and lung cancer are therefore experiencing preterminal disease and are likely to require similar medical and social services. The UK Department of Health’s expert report published in 19922 advocated the extension of palliative care services to all who need them, whatever their diagnosis. Since then, the availability and provision of holistic supportive care to patients dying from non-malignant disease has become a topical issue for palliative medicine.1 However, while countries such as the USA admit a high proportion of non-cancer patients to hospice inpatient units (30% in 1994–5),3 the UK lags far behind, concentrating these services mainly on cancer patients with only a small proportion of hospice inpatients (4% in 1995) suffering from diseases other than cancer.4

Severe COPD and advanced lung cancer are both progressive diseases which are often managed by the same health care professionals such as primary care teams. However, the palliative care needs of patients with these two diseases have never previously been compared. The publication of the paper by Gore et al in this issue of Thorax is therefore of interest because it provides further evidence that the care needs of patients with severe COPD should be considered in the same way as those with lung cancer.5 This is an important message for medical practice where the relevance of palliative care skills to patients with terminal non-malignant conditions is recognised but where the framework for extending these services beyond cancer patients is still in need of development.6

The aim of palliative care is the achievement of the best quality of life for patients and their families.6 This aim is often assessed by measures of quality of life. The concept of quality of life, however, is complex and difficult to define, being both individual and multidimensional and, although many instruments exist which attempt to quantify it, measurement is difficult. In the medical context, quality of life is usually measured in terms of physical symptoms, psychological well being, and limitations on physical and social functioning. Thus, the majority of instruments in common use are health related quality of life (HRQoL) measures. Generic measures, which are applicable to anyone including those in good health, are useful for comparing diseases or for measuring disease related impairment by comparisons with data from “normal” populations. There is still some debate, however, about the applicability of generic instruments in chronic disease and the Medical Outcomes Study Short Form 36 (MOS SF-36), for example, has been shown to have limitations in some groups of patients.7 Disease specific instruments, by comparison, have items relevant to the condition being studied. They are therefore more sensitive to change and can be used to measure outcomes and evaluate the effects of treatment or other interventions. The St George’s Respiratory Questionnaire (SGRQ)10 and the Chronic Respiratory Disease Questionnaire (CRDQ)11 are examples of questionnaires frequently used in studies of respiratory patients to measure HRQoL. In studies of COPD these instruments have shown how interventions such as rehabilitation programmes and inhaled corticosteroids can improve quality of life for patients.12 13 They have also provided evidence that, as the disease progresses, quality of life declines but, in common with generic measures, they do not always correlate strongly with objective measures of physical function such as forced expiratory volume in one second (FEV1) in patients with COPD.14 This reflects the fact that quality of life is not only a highly personal concept but also a dynamic one, changing as individuals adjust to changes in their health status and react to experience, interpersonal relationships, and altering roles.

In cancer studies the European Organisation for the Research and Treatment of Cancer Core questionnaire (EORTC QLQ-C30) and the site specific module LC-17 for lung cancer is a well validated and widely used outcome measure.15 Many cancer studies now include HRQoL as an end point but sequential data for lung cancer are less common than for COPD as worsening symptoms and shorter survival times mean that drop out from studies is high. Some studies have reported longitudinal quality of life data for lung cancer patients using various instruments but these have mainly been concerned with demonstrating differences between treatment modalities.16

Gore et al propose that patients with COPD experience worse quality of life than those with lung cancer and that COPD care is less well resourced in the UK, despite the similar patterns of morbidity and mortality that both diseases produce. However, readers should be aware of the methodological limitations of this study which, while not entirely negating the conclusion, mean that some caution is needed in the interpretation of the results.

The sampling method used by the authors produced two study populations which are atypical in sex distribution and disease severity, and in length of survival in the lung cancer group. Of the 28 000 deaths from COPD in England and Wales in 1999, 56% were men and 44% were women. The male:female proportions were reversed in the study sample which, while it may be explained by local variations in the prevalence of COPD in men and women, is relevant here because the lung cancer group studied was biased toward male sex: 72% men/28% women compared with national figures of 62% and 38%, respectively. Health
surveys in random samples of the general population consistently report sex differences in physical symptom reporting, and female sex is associated with higher levels of symptomatology and lower self-reported health status.17 Although this effect is not always seen in specific groups of cancer patients, it is relevant to the generic assessment of HRQoL. Women, both in cancer studies and in other disorders, also report higher anxiety levels measured by the Hospital Anxiety and Depression Scale (HADS).18

The medical criteria used for the selection of patients also have implications for the generalisability of the results. By selecting only COPD patients who had had at least one admission for hypercapnic respiratory failure, the authors may have excluded many more stable emphysematous patients with severe disease and an FEV1 of less than 0.75 l. By intentionally identifying end stage COPD, they selected a group of very severely impaired patients whereas, in the cancer group, the median interval between diagnosis and interview of one year was twice the median survival time of about six months for patients with non-small cell lung cancer (NSCLC) in the UK. Thus, while not explicitly excluding patients with a poorer prognosis, failing to study a representative number of them has resulted in an atypical sample of patients with NSCLC.

The health related quality of life data presented in this paper gave generic and disease specific scores for two sample groups which showed the COPD group to be reporting worse quality of life on comparable dimensions. This is an important result, notwithstanding any reservations related to the study populations used, but the levels of impairment need to be placed in context in order to fully understand their meaning.

It is difficult to compare different studies of quality of life in lung cancer patients because of the large number of cancer specific instruments available to researchers and the various methods used to present the results. Gore et al commented that their patients reported disease specific scores comparable to those studied by Aaronson et al in 1993.19 However, 90% of the patients in the study by Aaronson and coworkers had a good performance status (WHO grade 0–2) which is probably not typical of NSCLC overall. In comparison, a recent study of 65 patients in the Netherlands with a poorer performance status receiving palliative radiotherapy for previously untreated, locally advanced, or metastatic NSCLC reported lower EORTC scores for emotional function.20 Similarly, the mean HADS scores are not easily comparable with other groups of NSCLC patients. Many authors opt for categorising HADS scores on the basis of “normal”, “borderline”, or “significant anxiety and depression” rather than quoting actual scores, while others present median scores and ranges which are appropriate summary statistics for this type of data.21 However, we are aware of one paper which reported mean HADS scores for a random sample of 751 Norwegian inoperable or relapsed patients with a variety of cancers including lung cancer. Compared with this study, the patients studied by Gore et al appeared to score much better on the HADS scale. Although not directly comparable, the Norwegian patients are representative of those who would require palliative care services at some stage.18

Scores for the SGRQ range from 0 to 100 with higher scores representing a worse level of functioning. The mean (SD) total scores of 72 (14)% for the SGRQ support the view that these patients with COPD were experiencing very severe disease compared with those in other studies using the same instrument. The ISOLDE study22 examined the effect of inhaled corticosteroids in 751 patients with moderate to severe COPD (FEV1 50% of predicted normal and at least 0.81 after bronchodilator) and reported baseline mean (SD) total scores of just under 50% for the SGRQ (placebo group, n = 375: 49.9 (17.4)%; treatment group, n = 376: 47.7 (17.6)%).

Effectively, Gore et al have compared long term survivors with long term sufferers; as not enough is known about the way individuals value the many aspects of quality of life—particularly in relation to illness—this comparison is not straightforward. The diagnosis of cancer is a devastating and emotive one but not all its impacts are persistently negative. Cancer patients have been shown, for example, to report more positive social experiences than a random sample of the population, possibly as a result of relatives and friends being brought closer together in a time of crisis.23 Depression measured on the HADS scale has also been shown to lessen as the interval from the diagnosis of cancer increases.19-21 In COPD the pattern is different; social isolation is common, as in many chronic and progressive diseases, as dependency increases and the burden of caring becomes harder for relatives and friends to cope with. HADS depression scores for patients with COPD mirror this, worsening as the disease progresses.24 Gore et al may indeed have identified a real and important difference in the overall quality of life in these two patient groups, but their findings need to be confirmed in further studies, ideally including NSCLC patients undergoing active treatment or those who have been diagnosed with more advanced disease.

The proposal that patients with COPD are less well served by the UK health care system than those suffering from lung cancer is one that respiratory health care professionals would intuitively accept. However, a survey by the British Thoracic Society in 199725 showed that fewer than 30% of lung cancer units then had access to a specialist cancer nurse. The assumption that there are more specialist cancer nurses than respiratory nurse specialists with an interest in COPD may therefore be flawed. Cancer is a high profile disease associated with death, pain, and suffering which touches the lives of many and is perceived as being worse than most other diseases by the general population. There is no doubt that more counselling and palliative care services are available for cancer patients, many funded by charitable organisations and staffed by volunteers. Patients with severe COPD are often disabled by their disease for longer, and have a mortality rate comparable to that of many common cancers. COPD should therefore be viewed as a disease with similarities to cancer and there is no moral reason to exclude this group of patients from a palliative care approach including access to inpatient facilities and outreach services. There is already good evidence to show that outreach support such as local rehabilitation programmes for patients with COPD improves quality of life and that the benefits are sustained.26 Palliative care professionals are already extending their services to patients with motor neurone disease and HIV/AIDS. Although further comparisons would be useful, this paper adds to the evidence that palliative care has a role in chronic and debilitating non-malignant diseases. As Archie Cochrane wrote in 1972: “Cure is rare but the need for care is widespread . . ”27 In the case of chronic irreversible conditions like COPD this remains very true today.

K M HILL
M F MUERS

Department of Respiratory Medicine,
Leeds General Infirmary,
Great George Street,
Leeds LS1 3EX, UK
amajones@ulth.northy.nhs.uk

Management of malignant pleural effusions

G Antunes, E Neville

Malignant pleural effusion is a common problem in respiratory medicine and oncology and in some series accounts for up to 50% of all pleural effusions. The median survival following diagnosis ranges from three to 12 months and is largely dependent upon the underlying malignancy. Currently, lung cancer is the most common metastatic tumour to the pleura in men and breast cancer in women. Both malignancies account for 50–65% of all malignant effusions while lymphomas, genitourinary, and gastrointestinal tumours account for a further 25%, and 7–15% of all malignant effusions have no identifiable primary. Malignant effusions result predominantly from obstruction and disruption of lymphatic channels by malignant cells. However, vascular endothelial growth factor (VEGF), a potent angiogenic mediator and promoter of endothelial permeability, is produced in significant amounts by diseased pleural tissue and is thought to play a part in the formation of malignant effusions and local tumour growth.

The general approach to managing malignant effusions is determined by symptoms (dyspnoea, exercise tolerance limitation, and chest discomfort), performance status of the patient, expected survival, and response of the known primary tumour to systemic treatment. Intervention options range from observation in the case of asymptomatic effusions through simple thoracentesis to more invasive methods such as thoracoscopy, pleuropertitoneal shunting, and pleurectomy. Repeated aspiration is favoured in patients with limited survival and poor performance status and obviates lengthy hospitalisation. In the patient with reasonable survival expectancy and good performance status, every attempt should be made to prevent recurrence of the effusion. Intercostal tube drainage with instillation of a sclerosing agent, resulting in the obliteration of the pleural space, is the most widely used and cost-effective method to control recurrent symptomatic malignant effusions.

Size of drainage tube

Over the last two decades several new developments have modified the method originally described by Adler and Sayek. By convention, large bore intercostal tubes (size 24–32 F) have been used for drainage of malignant effusions and intrapleural administration of sclerosing agents. These large tubes are frequently associated with significant discomfort to patients and restrict mobility. Studies using small bore catheters (8–14 F) have reported similar success rates to those using large bore tubes, and small bore catheters are better tolerated and associated with less discomfort. In the only controlled randomised study published to date, no significant difference was seen in the pleurodesis success rate but larger randomised studies are required to confirm these results. A further potential advantage of the small bore catheter is in the area of ambulatory treatment of malignant effusions. Patz et al, using small bore catheters (10 F) and bleomycin as a sclerosing agent, achieved a modest pleurodesis success rate of 79% in outpatients.

When to sclerose

Lung re-expansion remains the most important requisite for successful pleural symphysis and sclerotherapy failures usually occur when complete lung re-expansion is not
achieved. The minimum amount of pleural fluid drainage (normally taken to be less than 150 ml/day) before sclero-
therapy appears to be less relevant for successful pleuro-
desis than confirmation of lung re-expansion radiologi-
cally. The role of intrapleural fibrinolytic agents in the
management of malignant effusions is in its infancy and
remains controversial. The potential role of thoracoscopy is yet to be fully realised

Patient rotation and tube clamping
Rotation of the patient following intrapleural administra-
tion of a sclerosing agent is no longer thought to be critical
to achieve distribution of the agent throughout the pleural
space. Recent evidence using radiolabelled tetracycline
revealed that the agent is dispersed throughout the pleural
space within seconds in a fairly uniform fashion. A sub-
sequent clinical randomised trial found no significant differ-
ence in the success rate or duration of fluid drainage
between the rotated and non-rotated patients. The prac-
tice of clamping of intercostal tubes or catheters
following instillation of a sclerosing agent is to be discour-
age. The reasons for this are based on the rapid dispersion
of the sclerosing agent, potential complications such as
tension pneumothorax in the presence of an unsuspected
persistent air leak, and a lack of good evidence for its use.
Removal of the intercostal tube or catheter should occur
within 72 hours of sclerotherapy provided the lung remains
fully expanded and there is a reduction in the rate of fluid
drainage.

Sclerosing agents
The ideal sclerosing agent will have a high molecular
weight, low regional and rapid systemic clearance, a steep
dose/response curve, and be well tolerated with minimal
side effects. Despite the evaluation of a large number of
agents, no ideal sclerosing agent exists. Poor study design
and disparate criteria for measuring response hamper
proper comparison of these agents. The choice of a sclero-
sing agent is thus largely dependent on the success rate or
efficacy, accessibility, safety, ease of administration, and
cost.

Tetracycline was, until 1998, the most popular and
widely used sclerosing agent via an intercostal tube in the
UK when its production was discontinued by the
manufacturer following its discontinuation in the USA in
1992. Tetracycline may still be imported from Europe
(Germany) at present but this supply may also cease in
the near future. Tetracycline has a modest efficacy (average
success rate 65%), an excellent safety profile, and it is rela-
tively inexpensive. It is well tolerated and side effects are
infrequent, mild, and transient. Other tetracycline
derivatives such as doxycycline and minocycline have only
been evaluated in small uncontrolled trials and neither is
available in the UK. Bleomycin is the most widely used antineoplastic agent
for sclerotherapy. Its mechanism of action is predominantly
as a chemical sclerosing agent similar to tetracycline and
sterile t alc. It is an effective sclerosant with an average suc-
cess rate of 60% and has an acceptable side effect profile.
However, its major limitation is the cost per treatment.

Sterile t alc is a trilayered magnesium silicate sheet and
was first used as a sclerosing agent in 1935. The modern
preparation is asbestos-free and is administered either as
talc poudrage at the time of thoracoscopy using an
atomiser or as talc slurry via an intercostal tube. Success
rates for talc poudrage and slurry range from 80% to 100%. Earlier studies quoted higher success rates for
talc poudrage than for talc slurry but Yim et al recently
found no significant difference between the two methods
with respect to success rate, duration of chest drainage,
hospital stay, and complications. Talc is usually well
tolerated and the most common side effects reported are
pleuritic chest pain and fever.

Adult respiratory distress syndrome (ARDS) or acute
talc pneumonitis is a rare and occasionally fatal complica-
tion of intrapleural administration of talc. The precise
mechanism leading to acute pneumonitis is unclear and
has been reported with both talc poudrage and slurry. ARDS or talc pneumonitis appears to be dose related, most
cases having been associated with doses in excess of 5 g. In
a recent study by York et al talc pneumonitis was reported
in eight cases of a series of 125 patients who underwent talc
slurry pleurodesis with a dose of 5 g. Closer scrutiny of
the study shows that five patients had radiological features
consistent with ARDS and only two patients required
mechanical ventilation. All eight cases received high dose
corticosteroids and survived to hospital discharge.

Surgical options
Pleuroperitoneal shunting is an acceptable palliative option
in patients with trapped lung and large refractory
malignant effusions. Insertion of the shunt is facilitated by
thoracoscopy or mini-thoracotomy and is usually well tol-
erated. Complications such as shunt occlusion, infection,
and tumour seeding are not infrequent and have
contributed to its low popularity. Although open pleurec-
tomy is a very effective method of achieving pleurodesis, it
has an unacceptable morbidity and mortality rate. Video-
assisted thoracoscopic pleurectomy appears to be a promis-
ing and much safer technique although experience is limi-
ted and it is not widely available.

Video-assisted thoracoscopic surgery (VATS) and medi-
cal thoracoscopy are widely used in continental Europe and
North America for both diagnostic and therapeutic
purposes in malignant effusions. Their therapeutic role
is well studied with pleurodesis success rates (talc
poudrage) of over 90%. The main indications for referral
are pleural effusions of undetermined aetiology after
repeated pleural fluid analysis and refractory malignant
effusions unresponsive to pleurodesis via an intercostal
tube.

Conclusions
There have been several advancements in the management
of malignant pleural effusions over the last two decades,
but further research is required. The exact mechanisms
involved in the formation of malignant effusions have yet to
be fully elucidated. Technical aspects such as the most
appropriate intercostal tube or catheter size need to be
established. Although sterile talc is the most effective scle-
rosing agent available at present, it is associated with a
potentially life-threatening—albeit rare—complication and
further efforts should be made to find an alternative agent.
The potential role of thoracoscopy is yet to be fully realised
in both the diagnosis and treatment of malignant pleural
Endoscopic ultrasound guided transoesophageal biopsy

Obtaining tissue from the mediastinum: endoscopic ultrasound guided transoesophageal biopsy

S A Roberts

Endoluminal or endoscopic ultrasound (EUS) was first attempted in 1957 by Wild and Reid who placed a mechanical ultrasound transducer in the rectum. It was not until 1975 that the upper gastrointestinal tract was examined when Rasmussen et al measured the stomach wall thickness with a 6 MHz transducer passed through the biopsy channel of a gastroscope. In the 1980s, with the development of a dedicated endoscope incorporating a mechanical ultrasound transducer, EUS became important in clinical practice. Accurate local and nodal staging of oesophageal, gastric and pancreatic tumours and assessment of stone disease in the biliary tract established EUS in the investigation of gastrointestinal disease. The accurate detection of mediastinal lymph nodes in oesophageal cancer had obvious implications for patients with lung cancer, and the role of EUS in lung cancer was first described in Japan in 1988.

superior accuracy of EUS in the nodal staging of lung cancer compared with computed tomographic (CT) scanning, although EUS is not yet used routinely in the preoperative staging of lung cancer in the UK.

Further technical advancement led to the development of the linear EUS probe. This allows passage of a needle through the biopsy channel of the endoscope, through the wall of the gastrointestinal tract, and into adjacent structures such as lymph nodes. The orientation of the ultrasound beam, parallel rather than perpendicular to the long axis of the endoscope or the transducer, allows continuous ultrasound imaging of structures such as lymph nodes. The technique has obvious implications for patients with lung cancer, and the role of EUS in lung cancer was first described in Japan in 1988. Further work confirmed the advantages of EUS in the nodal staging of lung cancer compared with computed tomographic (CT) scanning, although EUS is not yet used routinely in the preoperative staging of lung cancer in the UK.

Endoscopic ultrasound guided transoesophageal biopsy

Obtaining tissue from the mediastinum: endoscopic ultrasound guided transoesophageal biopsy

S A Roberts

Endoluminal or endoscopic ultrasound (EUS) was first attempted in 1957 by Wild and Reid who placed a mechanical ultrasound transducer in the rectum. It was not until 1975 that the upper gastrointestinal tract was examined when Rasmussen et al measured the stomach wall thickness with a 6 MHz transducer passed through the biopsy channel of a gastroscope. In the 1980s, with the development of a dedicated endoscope incorporating a mechanical ultrasound transducer, EUS became important in clinical practice. Accurate local and nodal staging of oesophageal, gastric and pancreatic tumours and assessment of stone disease in the biliary tract established EUS in the investigation of gastrointestinal disease.

superior accuracy of EUS in the nodal staging of lung cancer compared with computed tomographic (CT) scanning, although EUS is not yet used routinely in the preoperative staging of lung cancer in the UK.

Further technical advancement led to the development of the linear EUS probe. This allows passage of a needle through the biopsy channel of the endoscope, through the wall of the gastrointestinal tract, and into adjacent structures such as lymph nodes. The orientation of the ultrasound beam, parallel rather than perpendicular to the long axis of the endoscope or the transducer, allows continuous ultrasound imaging of structures such as lymph nodes.
case in most patients, it is safe, and requires only conscious sedation. Complications related to EUS-FNA reported by Wiersema et al in 457 patients with 554 lesions occurred in only three patients who underwent aspiration of cystic pancreatic lesions (haemorrhage and fever). This series included 192 peri-intestinal lymph node biopsies with no complications.13

Does the technique have a role? Sensitivities of 85–92%14 15 for malignancy in lymph nodes suggest that EUS-FNA is worth considering before more invasive techniques. For example, EUS-FNA can be used before mediastinoscopy where bronchoscopic biopsy specimens have failed to provide a tissue diagnosis. Fritscher-Ravens et al describe 16 patients with an intrapulmonary lesion on the chest radiograph or CT scan who had inconclusive pathology results obtained at bronchoscopy with forceps biopsy and/or brush cytology.15 Of the 10 patients with a final diagnosis of malignancy, this was established with EUS-FNA in nine. Transcarinal needle aspiration was not performed in this study which might have obviated the need for EUS-FNA in some of these patients.

A more systematic approach to the role of EUS-FNA has been explored as part of a routine staging protocol for patients with known or presumed lung cancer.10 11 Gress et al16 reported that EUS-FNA avoided unnecessary surgery in 14 of 24 patients, confirming N2 disease in two and N3 disease in 12 patients. Mediastinoscopy, altogether more invasive and expensive than EUS-FNA, was avoided in all 24 patients with only one false negative result. Aabakken et al17 have also shown that EUS-FNA is a cost effective alternative to mediastinoscopy/mediastinotomy in a comparison using a cost effectiveness model.18 However, there are few proper comparative data between the techniques. Despite small patient numbers, in the only comparative study of EUS-FNA with mediastinoscopy to date Serna et al19 reasonably concluded that the techniques may be complementary, mediastinoscopy targeting the upper and anterior mediastinum and EUS-FNA targeting subcarinal and posterior mediastinal lesions.20 Further comparative data are required to assess properly its role as part of formal lung cancer staging protocols but the initial pointers are favourable.

Let us briefly consider some of the other relatively non-invasive techniques for obtaining tissue. Percutaneous needle biopsy with CT guidance is an alternative which was reported to have a remarkably high sensitivity of 98% (40 of 41) for diagnosing carcinoma in one series,20 although this was in a selected population thought to have lung cancer. In the same series, however, pneumothorax occurred in 34% of patients with a chest tube being required in 14%. Another limiting factor in this study was that biopsy samples were only taken from nodes with a diameter greater than 1.5 cm, although biopsy samples were successfully taken from nodes with a diameter of 1.2 cm in another series21 which again had a significant pneumothorax rate of 22%. In our experience nodes of less than 1 cm in diameter can be aspirated relatively easily and without complication with EUS-FNA.22 Although there are disadvantages to the percutaneous approach, particularly the higher complication rate, a major advantage is that no specialist equipment is necessary as virtually all district hospitals have a CT scanner. This, of course, assumes that the radiological skill, inclination, and time to take biopsy samples is available.

Transbronchial/carinal needle aspiration (TCNA) performed at the time of flexible bronchoscopy has a variable yield and sensitivities ranging from 34% to 89%.23 24 More recently there have been preliminary reports of the procedure being assisted by CT scanning or endobronchial ultrasound. With CT guidance the sensitivity increased from 20% to 60%24 and, on a per node basis, a sensitivity of 88% was achieved when guided by virtual bronchoscopy.25 Shannon et al reported that EUS guidance reduces the number of passes required, but does not increase the already high yield with EUS guidance.26 The sensitivities of lymph node staging with and without EUS guidance were 82% and 90%, respectively, in this series with on site cytopathology. One of the problems with TCNA is that the promising results obtained in academic centres have not necessarily been repeated in smaller units. This variability in yield may have prevented the more widespread use of the technique. When used for staging lung cancer, concerns about TCNA have also been raised regarding false positive results caused by contamination of the specimen with malignant cells from the lumen.27 28 This should not be a problem with the transoesophageal approach.

In conclusion, the role of EUS-FNA in assessing mediastinal pathology needs greater attention. It is clearly a useful technique and the tissue obtained safely and relatively non-invasively will influence patient management in the majority of cases. There are no more than five centres performing this procedure in the UK; three years ago there was only one. For a proper assessment of its role in preoperative staging of lung cancer, more centres need to perform the technique which is relatively simple to learn and appropriate comparative studies could then be set up. EUS-FNA was primarily developed with gastrointestinal disease in mind, particularly staging and obtaining tissue from pancreatic cancer. Biopsy specimens can also be taken from lymph nodes adjacent to the gastrointestinal tract below the diaphragm. The indications have expanded further with EUS guided pancreatic pseudocyst drainage and coeliac plexus neurolysis for pain relief. The ultrasound machine required (Hilitek) can be used for general ultrasound work and the cost of setting up this service may be spread by consultation with gastrointestinal and radiological colleagues. EUS has moved on considerably from the rectum since 1957 and there is now adequate evidence for an increased role in the management of a number of diseases across several specialities.

S A ROBERTS

Singleton Hospital,
Swansea SA2 8QA, UK
ashley.roberts@swansea-tr.wales.nhs.uk


www.thoraxjnl.com

Thorax: first published as 10.1136/thorax.55.12.983 on 1 December 2000. Downloaded from http://thorax.bmj.com/ on April 26, 2022 by guest. Protected by copyright.


